- RWS Holdings has completed the acquisition of PharmaQuest Limited for a cash consideration of £2.3 million.

The deal is in line with RWS's strategy of organic and acquisitive growth.

PharmaQuest specialises in providing high quality translation and linguistic validation of patient reported outcome measures resulting from clinical trials conducted globally.

RWS is a provider of intellectual property support services (patent translations and technical searches) and commercial translations.

At 8:25am: [LON:RWS] RWS Holdings share price was +1.5p at 640p

Story provided by